[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555167":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":28,"responsibleParty":45,"collaborators":20,"id":47,"slug":20,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":20,"enrollmentInfo":55,"targetDuration":20,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":20,"overallStatus":31,"whyStopped":20,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"University Health Network, Toronto","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"2xHDR Brachytherapy","EXPERIMENTAL","Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed recurrence after Postoperative Radiotherapy.",[13],"Radiation: High Dose Rate Brachytherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","High Dose Rate Brachytherapy","2 fractions of MRI-guided HDR Brachytherapy (13Gy each) delivered over 14 days (± 7 days).",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":26,"email":27},"Peter Chung, MD","CONTACT","416-946-4501","3374","peter.chung@uhn.ca",[29],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Princess Margaret Cancer Centre","RECRUITING","Toronto","Ontario","M5G1Z5","Canada",{"type":37,"coordinates":38},"Point",[39,40],-79.39864,43.70643,{"lat":40,"lon":39},[43],{"name":44,"role":24,"phone":25,"phoneExt":26,"email":27},"Peter Chung",{"type":46,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100555167",false,"NCT06508567","Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era","SHAPE-PSMA","Inclusion Criteria:\n\n1. Patients who received previous RT to the prostate bed +\u002F- pelvic nodal regions\n2. Prostate-bed recurrence identified by biopsy and\u002For MRI and\u002For PSMA-PET scan\n3. At least two continuous PSA elevations post RT and PSA above 0.2 ng\u002Fdl\n4. With or without ADT PSA doubling time from nadir greater than 6 months\n5. ECOG 0-2\n6. Age greater than 18 years\n\nExclusion Criteria:\n\n1. Radiological (e.g. PSMA PET, CT, MRI or bone scan) evidence of or distant metastases\n2. History of ≥G3 gastrointestinal (GI) and genitourinary (GU) toxicities following RT\n3. Any contraindications to MR and\u002For brachytherapy","MALE","18 Years",{"count":56,"type":57},20,"ESTIMATED","INTERVENTIONAL",[60],"NA","This is an interventional, single-centre, single-arm, non-randomized, prospective, feasibility trial investigating salvage MR-guided High-Dose-Rate brachytherapy for prostate bed recurrence after postoperative radiotherapy.",[63,64],"Prostate Cancer Recurrent","Prostate Cancer","2026-05-21",{"date":67,"type":68},"2026-05-26","ACTUAL",{"date":70,"type":68},"2024-08-08",{"date":72,"type":57},"2031-03-01",{"name":5,"class":6},1]